Managing Disease Progression After TACE
The panelist discusses how the patient underwent transarterial chemoembolization (TACE) 3 times with an initial partial response. However, at the end of the 6-month treatment period, the patient had disease progression. The panelist advises that the best treatment option for the patient would be systemic therapy.
Video content above is prompted by the following:
- The patient progresses within 1 year of TACE. Please discuss a suitable treatment approach to address disease progression.
- Review case details from the patient’s 6-month follow-up.
- What would your treatment approach look like?
- How would you determine which treatment option would be best for this patient?
Recent Videos
Related Content
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024Article
During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
